Catalyzing the Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalyzing the Synthesis
Researchers develop various catalytic approaches for improving yield, purity, stereoselectivity, and process conditions.


Pharmaceutical Technology
pp. 44-50

Making acids behave like bases

A research team lead by Guy Bertrand, a distinguished professor of chemistry at the University of California at Riverside, recently reported on the use of boron-based compounds to build Lewis bases.

The researchers reported on the synthesis and characterization of a neutral tricoordinate organoboron isoelectronic with amines. The neutral tricoordinate boron derivative acted as a Lewis base and underwent one-electron oxidation into the corresponding radical cation. These compounds were the parent borylene and borinylium, respectively, stabilized by two cyclic (alkyl)(amino) carbenes. Ab initio calculations showed that the highest occupied molecular orbital of the borane and the singly occupied molecular orbital of the radical cation were essentially a pair and a single electron, respectively, in the p(p) orbital of boron (7).

"The result is totally counterintuitive," said Bertrand, in an July 28, 2011, University of California at Riverside press release. "...But we have achieved it. We have transformed boron compounds into nitrogen-like compounds. In other words, we have made acids behave like bases."

Nitrogen- or phosphorus-based compounds are commonly used as ligands in catalysts. "The trouble with using phosphorus-based catalysts is that phosphorus is toxic and it can contaminate the end products," Bertrand said. "Our work shows that it is now possible to replace phosphorus ligands in catalysts with boron ligands. And boron is not toxic," he added. Researchers at Philipps–Universitat in Marburg, Germany, also contributed to the study.

References

1. J.N.H. Reek et. al., J. Am. Chem. Soc., online DOI: 10.1021/ja208589, Sept. 30, 2011.

2. S. Ritter, Chem. & Eng. News 89 (42), 13 (2011).

3. J.M. John and S.H. Bergens, Angew. Chem. Int. Ed. 50 (44), 10377–10380 (2011).

4. K.C. Harper and M.S. Singer, Science 333 (6051), 1875–1878 (2011).

5. F. Meyer nd C. Limber, eds., "Preface" in Organometallic Oxidation Catalysis (Springer, New York, 2007).

6. J.T. Yates, Jr., et al., Science 333 (6043), 736–739 (2011).

7. G. Bertrand, Science 333 (6042), 610–613 (2011).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
21%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here